NCT03844100View on ClinicalTrials.gov

Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

August 4, 2021

Study Completion Date

August 4, 2021

Conditions
DyspepsiaBiliary Dysplasia
Interventions
DRUG

efficacy and safety of CNU® Capsule

All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.

Trial Locations (6)

13496

CHA Bundang Medical Center, Seongnam

18450

Dongtan Sacred Heart Hospital, Hwaseong-si

21565

Gachon University Gil Medical Center, Incheon

22332

In Ha University Hospital, Incheon

31151

Soon Chun Hyang University Hospital, Cheonan, Cheonan

06229

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

Gangnam Severance Hospital

OTHER

NCT03844100 - Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients | Biotech Hunter | Biotech Hunter